Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shares are moving lower Friday after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, following a re-examination, confirmed its June 2024 negative opinion on the marketing authorization application of intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration.

The Details: Over time, geographic atrophy destroys retinal cells which leads to vision loss.

"We are deeply disappointed by this outcome, which leaves millions of Europeans with GA without a treatment for this irreversible form of blindness," said Cedric Francois, CEO and Apellis co-founder.

"This CHMP opinion was made despite broad support for pegcetacoplan from the European retina community and multiple dissenting votes by CHMP members who supported a path to approval."

How To Buy Apellis Pharmaceuticals Shares

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Apellis Pharmaceuticals (NASDAQ:APLS)'s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

APLS Price Action: At the time of writing, Apellis Pharmaceuticals stock is moving 10.50% lower at $32.95, according to data from Benzinga Pro.

Image: Unsplash/ Volodymyr Hryshchenko